Traws Pharma Inc (NAS:TRAW)

$ 13.42 2.02 (17.72%) Market Cap: 40.60 Mil Enterprise Value: 29.08 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Q2 2024 Traws Pharma Inc Earnings Call Transcript
Aug 15, 2024

$9 (+4.93%)

Earnings
Q3 2023 Onconova Therapeutics Inc Earnings Call Transcript
Nov 14, 2023

$16.5 (+1.69%)

Earnings
Q2 2023 Onconova Therapeutics Inc Earnings Call Transcript
Aug 10, 2023

$25.5 (+3.98%)

Earnings
Q1 2023 Onconova Therapeutics Inc Earnings Call Transcript
May 15, 2023

$29.5 (-5.60%)

Earnings
Q4 2022 Onconova Therapeutics Inc Earnings Call Transcript
Mar 16, 2023

$19.63 (+7.09%)

Earnings
Q3 2022 Onconova Therapeutics Inc Earnings Call Transcript
Nov 14, 2022

$22 (+23.09%)

Earnings
Q2 2022 Onconova Therapeutics Inc Earnings Call Transcript
Aug 11, 2022

$32.94 (+2.14%)

Earnings
Q1 2022 Onconova Therapeutics Inc Earnings Call Transcript
May 11, 2022

$27 (-8.86%)

Earnings
Q4 2021 Onconova Therapeutics Inc Earnings Call Transcript
Mar 17, 2022

$46.5 (+16.25%)

Earnings
Onconova Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
Onconova Therapeutics Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
Nov 22, 2021
Q3 2021 Onconova Therapeutics Inc Earnings Call Transcript
Nov 11, 2021

$87.25 (+2.95%)

Earnings
Onconova Therapeutics Inc Expert Overview from Key Opinion Leaders Webinar Transcript
Sep 22, 2021
Q2 2021 Onconova Therapeutics Inc Earnings Call Transcript
Aug 12, 2021

$129.5 (-0.19%)

Earnings
Q1 2021 Onconova Therapeutics Inc Earnings Call Transcript
May 17, 2021

$231.37 (+17.30%)

Earnings
Onconova Therapeutics Inc Extraordinary Shareholders Meeting Transcript
Apr 30, 2021
Onconova Therapeutics Inc Extraordinary Shareholders Meeting Transcript
Apr 01, 2021
Full Year 2020 Onconova Therapeutics Inc Earnings Call Transcript
Mar 11, 2021

$423.75 (+1.80%)

Earnings
Onconova Therapeutics Inc Annual Shareholders Meeting Transcript
Mar 04, 2021
Q3 2020 Onconova Therapeutics Inc Earnings Call Transcript
Nov 12, 2020

$109.42 (+7.99%)

Earnings
Onconova Therapeutics, Inc. - Special Call Transcript
Aug 24, 2020
Q2 2020 Onconova Therapeutics Inc Earnings Call Transcript
Aug 12, 2020

$397.5 (-3.64%)

Earnings
Onconova Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 26, 2020
Onconova Therapeutics Inc Annual Shareholders Meeting Transcript
May 27, 2020
Q1 2020 Onconova Therapeutics Inc Earnings Call Transcript
May 14, 2020

$135 (+0.70%)

Earnings
Q4 2019 Onconova Therapeutics Inc Earnings Call Transcript
Mar 24, 2020

$137.74 (+15.58%)

Earnings
Q2 2019 Onconova Therapeutics Inc Earnings Call Transcript
Aug 14, 2019

$855 (-2.15%)

Earnings
Q1 2019 Onconova Therapeutics Inc Earnings Call Transcript
May 14, 2019

$1559.99 (-3.26%)

Earnings
Full Year 2018 Onconova Therapeutics Inc Earnings Call Transcript
Mar 26, 2019

$1387.49 (-10.41%)

Earnings

Q2 2024 Traws Pharma Inc Earnings Call Transcript

Aug 15, 2024 / 12:00PM GMT

Release Date Price: $9 (+4.93%)

Transcript 8-K10-Q

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Traws Pharma, Inc. corporate update call. (Operator Instructions) As a reminder, this call is being recorded today, August 15, 2024. At this time, I would like to turn the call over to Bruce Mackle of Lifesci Advisors.

Bruce Mackle

Lifesci Advisors - Investor Relations

Thank you, operator, and welcome, everyone, to Traws Pharma, Inc.'s corporate update conference call. This morning, Traws issued a press release reporting its second quarter 2024 financial results and corporate update. If you have not yet seen this press release, it is available in the Investors & Media section of the company's website at www.trawspharma.com. Following my introduction, we will hear from Traws' Chief Executive Officer, Dr. Werner Cautreels; and Chief Financial Officer, Mark Guerin.

Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the safe harbor

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.